Leadership

Theodore (Ted) T. Ashburn, M.D., Ph.D.
President, CEO

Theodore T. Ashburn, M.D., Ph.D. - President and CEO at Oncorus

Theodore (Ted) T. Ashburn, M.D., Ph.D.

President, CEO

Christophe Quéva, Ph.D.
Chief Scientific Officer

Christophe Quéva, Ph.D. - Chief Scientific Officer at Oncorus

Christophe Quéva, Ph.D.

Chief Scientific Officer

Lorena Lerner, Ph.D.
Senior Director, Molecular Biology

Lorena Lerner, Ph.D. - Senior Director, Molecular Biology

Lorena Lerner, Ph.D.

Senior Director, Molecular Biology

Brian B. Haines, PhD
Senior Director of Pharmacology/Toxicology

Brian B. Haines, PhD - Senior Director of Pharmacology/Toxicology

Brian B. Haines, PhD

Senior Director of Pharmacology/Toxicology

Stephanie Duncanson, PhD
Director of Corporate Strategy & Business Development

Stephanie Duncanson, PhD - Director of Corporate Strategy & Business Development

Stephanie Duncanson, PhD

Director of Corporate Strategy & Business Development

John M. Goldberg, MD
Senior Vice President of Clinical Development

John M. Goldberg, MD. - Senior Vice President of Clinical Development

John M. Goldberg, MD

Senior Vice President of Clinical Development

Tooba Cheema, PhD
Director of Translational Medicine and Biomarkers

Tooba Cheema, PhD - Director of Translational Medicine and Biomarkers

Tooba Cheema, PhD

Director of Translational Medicine and Biomarkers

Brett M. Belongia, PhD
Senior Director of CMC Operations

Brett M. Belongia, PhD - Senior Director of CMC Operations

Brett M. Belongia, PhD

Senior Director of CMC Operations

Theodore T. Ashburn, M.D., Ph.D. - President and CEO at Oncorus

Theodore (Ted) T. Ashburn, M.D., Ph.D.
President, CEO

Before becoming Oncorus’ President, CEO and a member of its Board of Directors, Ted was Head of Oncology Development at Moderna Therapeutics where he was responsible for overall design, integration and execution of Moderna’s clinical-stage oncology programs. Prior to this role, he led the development of Moderna’s Personalized Cancer Vaccine programs. Previously, Ted was Senior Vice President of Product Strategy and Operations at Dicerna Pharmaceuticals and also the Global Product Head for Leukine® (sargramostim) and Elitek®/Fasturtec® (rasburicase) for Sanofi Oncology. In this latter role, Dr. Ashburn provided global leadership for R&D and global marketing and led regional commercial teams to identify, develop, prioritize and execute new commercialization and life-cycle management strategies to drive growth. He was also responsible for negotiating and implementing Sanofi’s 2013 supply, stockpiling and R&D contract with the U.S. Government’s Biomedical Advanced Research and Development Authority (BARDA).

Ted joined Sanofi Oncology from Genzyme’s Corporate Development group where he led business development efforts for several of Genzyme’s franchises including transplant, oncology and rare diseases and was responsible for Genzyme’s 2009 deal with ViroPharma. Prior to joining Genzyme, he worked for privately held Dynogen Pharmaceuticals, Inc. and the venture capital firm Oxford Bioscience Partners. While at Oxford he co-founded both Dynogen and BrainCells, Inc. and led investments in Alantos Pharmaceuticals (acquired in June, 2007 by Amgen for $300 million in cash) and superDimension, Ltd. (acquired by Covidien in March, 2012 for more than $300 million). Before joining Oxford, Ted started his career at Pfizer Inc. where he was involved in the analysis of several acquisition and new business opportunities including Pfizer’s acquisition of Warner-Lambert in 2001.

Ted graduated magna cum laude from Ball State University where he studied chemistry and computer science. He earned his M.D. from Harvard Medical School and Ph.D. in organic chemistry from the Massachusetts Institute of Technology.

Christophe Quéva, Ph.D. Chief Scientific Officer at Oncorus

Christophe Quéva, Ph.D.
Chief Scientific Officer

Christophe Quéva, Ph.D., is Chief Scientific Officer and Senior Vice President, Research. Christophe is responsible for directing and advancing the company’s development program based on its next-generation immunotherapy platform of oncolytic viruses. An industry veteran, Christophe has nearly two decades’ immuno-oncology experience and successful portfolio-building track record from target identification and development through regulatory approval.

Prior to joining Oncorus, Christophe was Chief Scientific Officer at iTeos Therapeutics where his responsibilities included leading the generation of an innovative immuno-oncology portfolio of small molecule and antibody programs and overseeing the company’s translational medicine strategy for its A2A antagonist and TIGIT programs. Before iTeos, he held successive senior positions at AstraZeneca, Amgen and Gilead Sciences where he led or supported drug discovery programs for oncology and inflammatory diseases, from target selection to commercial approval for small molecules and biologics.

A holder of five patents and widely published, Christophe trained as a post-doctoral fellow at the Fred Hutchinson Cancer Research Center in Seattle after receiving his Ph.D. in Life and Health Sciences from the University of Lille, France.

Lorena Lerner, Ph.D. - Senior Director, Molecular Biology at Oncorus

Lorena Lerner, Ph.D.
Senior Director, Molecular Biology

Lorena Lerner Ph.D. is the Senior Director of Molecular Biology at Oncorus, where she is leading the efforts to engineer more potent and safer novel armed oncolytic viral vectors for the treatment of solid tumors.

Lorena is an experienced cancer biologist with a proven track record of managing and advancing projects, from early discovery into clinical development. Most recently, Lorena served as Director of Biology at Quiet Therapeutics, where she was responsible for leading the development of proprietary nanotechnology platform, identifying potent immunotherapy target candidates and optimizing vector design. Prior to Quiet, she served as Director of Target Discovery at Scholar Rock and held positions of increasing responsibilities at AVEO Oncology, where she pioneered and executed the development of AV-380, a cancer cachexia program targeting GDF15, from target identification, validation and antibody discovery through preclinical development and out-licensing enterprises.

Lorena received an MSc in Molecular Biology and a PhD in Biochemistry from University of Buenos Aires. She completed post-doctoral research fellowship in Molecular and Cellular Biology with Professor James E. Darnell at Rockefeller University. Her academic training focused in the field of gene regulation and cancer molecular biology. Lorena is a co-inventor of numerous patents and high-impact, peer-reviewed manuscripts and abstracts.

Brian B. Haines, PhD - Senior Director of Pharmacology/Toxicology

Brian B. Haines, PhD.
Senior Director of Pharmacology/Toxicology

Brian is the Senior Director of Pharmacology/Toxicology at Oncorus, where he leads a group involved in the evaluation of preclinical efficacy, immunological mechanisms of action, and nonclinical safety-toxicology of Oncorus’ oncolytic virus (OV) candidates.

Before Oncorus, Dr. Haines spent 12 years at Merck (MSD), where he was involved in the generation and characterization of novel translational immuno-oncology (IO) models, and led the pharmacology efforts for several IO programs, including those involving immune checkpoints, metabolic targets, or oncolytic virus approaches.

John M. Goldberg, MD. - Senior Vice President of Clinical Development

John M. Goldberg, MD.
Senior Vice President of Clinical Development

John is Senior Vice President of Clinical Development at Oncorus. In collaboration with the scientific and manufacturing teams, he is responsible for driving the initial studies of Oncorus’s clinical candidates, and for the ongoing development of clinical and regulatory strategies.

His prior roles include Senior Medical Director at H3 Biomedicine, clinical development at Agenus, and the leadership of the pediatric oncology Phase 1 program at the University of Miami. John’s immunotherapy experience includes the design of first-in-human of neo-antigen vaccines, design, oversite and conduct of dendritic cell vaccine and GVAX trials, as well as check point inhibitors and costimulatory agonists. He is a practicing pediatric oncologist with 12 years of experience treating children with cancer and enrolling patients to phase 1 trials.

John received his pediatric hematology oncology training at the Dana-Farber Cancer Institute and Children’s Hospital Boston, and his general pediatrics training at the University of Rochester. John is a graduate of the University of Massachusetts Medical School and the college of the University of Chicago.

Tooba Cheema, PhD - Director of Translational Medicine and Biomarkers

Tooba Cheema, PhD
Director of Translational Medicine and Biomarkers

Tooba is the Director of Translational Medicine and Biomarkers at Oncorus where she is responsible for leading translational research and advancing the biomarker strategy of the immunotherapy platform of oncolytic viruses into the clinic.

Prior to Oncorus, Tooba has years of immuno-oncology experience helping advance T cell therapies in combination with antibodies for hematological and solid tumor indications at Unum Therapeutics, and biological characterization of biologics and biosimilars for autoimmune and oncology indications at Momenta Pharmaceuticals.

Tooba received her post-doctoral training at Massachusetts General Hospital under the fellowship from the American Brain Tumor Association, evaluating combination therapies with oncolytic virus for the treatment of glioblastoma. Tooba received her Ph.D. in Pharmacology from the University of Michigan-Ann Arbor and her Bachelors in Biochemistry from Tufts University. Tooba is also an active member and past-president of MASS AWIS serving to mentor and enhance the awareness and participation of women in science.

Stephanie Duncanson, PhD - Director of Corporate Strategy & Business Development

Stephanie Duncanson, PhD
Director of Corporate Strategy & Business Development

Stephanie Duncanson, Ph.D., is the Director of Corporate Strategy & Business Development at Oncorus. Stephanie is responsible for identifying, sourcing, and driving strategic opportunities for Oncorus’ next-generation oncolytic virus platforms. Additionally, she serves as the head of Business Development, alliance manager, and leads IP portfolio development.

Prior to joining Oncorus, Stephanie was a Consultant at Clarion Healthcare, providing strategic support, guidance, and planning to a broad range of biopharmaceutical companies. Stephanie received her Ph.D. in Bioengineering from Georgia Institute of Technology with a focus in cell & gene therapy, and completed her B.S. in Chemical Engineering at Northeastern University.

Brett M. Belongia, PhD - Senior Director of CMC Operations

Brett M. Belongia, PhD.
Senior Director of CMC Operations

Brett is the Senior Director of CMC Operations. He and his team are responsible for the strategic direction and operational responsibilities related to the manufacturing, development and quality of oncolytic virus’s from early stage clinical development through commercialization.

Most recently, Brett was the Director of Technical Operations at Momenta Pharmaceuticals where he was responsible for the management of external manufacturing activities of novel proteins. Brett’s prior roles included responsibility for operation of a large scale development laboratory and upstream process development teams for biosimilar monoclonal antibody treatments.

Brett is the inventor on 13 patents and an author on multiple publications. Brett received his Ph.D. in Chemical Engineering from The University of Arizona after completing his BS in Chemical Engineering at The University of Wisconsin – Madison.